--- title: "AstraZeneca offers $10 billion for Rhythm Pharmaceuticals" publication: "MediaBias News" url: "https://mediabias.news/business/astrazeneca-offers-10-billion-for-rhythm-pharmaceuticals" api: "https://mediabias.news/api/v1/stories/astrazeneca-offers-10-billion-for-rhythm-pharmaceuticals" markdown: "https://mediabias.news/business/astrazeneca-offers-10-billion-for-rhythm-pharmaceuticals.md" audio: "https://mediabias.news/api/audio/astrazeneca-offers-10-billion-for-rhythm-pharmaceuticals" category: "Business & Economy" area: "United States" published: "2026-11-05T10:45:48.718Z" source_reported: "2026-11-05T10:11:00.000Z" updated: "2026-11-05T10:45:48.718Z" trust_score: 53 critic_score: 87 hype_score: 15 assessment_type: "coverage-and-source-reporting-analysis" fact_check_status: "not-performed" coverage_measured: "2026-11-05T10:15:10.885Z" --- # AstraZeneca offers $10 billion for Rhythm Pharmaceuticals *The pharmaceutical giant's bid for the obesity drugmaker includes milestone payments.* **Scores for the source reporting** (0-100, assessing the original journalism this article was written from, not this write-up): - Trust 53 of 100, higher is better. Trust 53: many sources named and figures cited, but central claim relies on anonymous sources and hedged language. - Craft 87 of 100, higher is better. Critic 87: clear context, quotes, specific data, and analyst comment show solid reporting. - Hype 15 of 100, lower is better. Hype 15: language is measured; no sensationalism or clickbait beyond factual headline. Scored by MediaBias News; method at https://mediabias.news/methodology. **The short version** - AstraZeneca has made a non-binding offer of about $10 billion for Rhythm Pharmaceuticals. - The offer values Rhythm at approximately $124 per share, including milestone payments. - Rhythm's shares rose 28% to close at $110.68 following the news. - The acquisition would be managed through AstraZeneca's rare-disease unit, Alexion. AstraZeneca has submitted a non-binding offer of approximately $10 billion to acquire Rhythm Pharmaceuticals, a company focused on therapies for rare metabolic diseases and obesity. The proposed deal values Rhythm at about $124 per share, a figure that includes potential milestone payments. Following the report of the offer, Rhythm's shares experienced a significant increase, closing up 28% at $110.68 on November 4, 2026. This surge gave the company a market capitalization of roughly $7.64 billion. The potential acquisition would be integrated into AstraZeneca's rare-disease business, Alexion. ## Disagreement on offer details While multiple reports state AstraZeneca made an offer of about $10 billion, the specific per-share price varies. Regional Media News, citing sources, reported AstraZeneca offered as much as $134 a share, including milestone payments. The Wall Street Journal, as reported by Reuters and WTVB, stated the offer was $124 per share last month. Dealroom.co and DiarioBitcoin also mentioned milestone payments as part of the proposal. ## What the coverage left out None of the centre or right-rated reports mentioned the U.S. Food and Drug Administration's expansion of the approved use of Rhythm's therapy Imcivree in March 2026, a fact established by the verified claims. ## Who covered it Shares of the 5 covering outlets with a published leaning rating: - Left: 0% (0) - Centre: 80% (4) - Right: 20% (1) 5 of 10 covering outlets carried no usable leaning rating and were excluded from those percentages. Coverage measured 2026-11-05T10:15:10.885Z. **Coverage watch:** developing. Checked 3 times; 0 checks found a material change. Most recently checked 2026-11-05T11:30:37.556Z. ## How the sides framed it ### Left No separate framing summary. ### Centre - The centre-rated reports led with AstraZeneca's $10 billion offer for Rhythm Pharmaceuticals. They highlighted that the bid was non-binding and included milestone payments. These reports also noted the subsequent rise in Rhythm's share price and its market capitalization. The digests mentioned that the acquisition would be pursued through AstraZeneca's rare-disease business, Alexion. ### Right - The right-rated report from Regional Media News led with AstraZeneca's $10 billion offer for obesity drugmaker Rhythm, citing sources. It specified that the offer was as much as $134 a share, including milestone achievements. The report also mentioned Rhythm's share price increase and market capitalization, and noted that the acquisition would be pursued through Alexion. It included commentary from Jefferies analyst Michael Leuchten, who called AstraZeneca's approach to acquiring rare disease assets 'entirely sensible'. ## Factuality profile of the covering outlets These are published factuality ratings of the outlets, not a verdict on whether this story or its claims are true. - mixed: 1 - high: 3 - unknown: 5 - veryHigh: 1 ## Verification scope This page compares coverage and scores the source reporting. It is not a ClaimReview verdict on whether the underlying event or claim is true. ## Original reporting this was written from - [Investing.com](https://investing.com/news/stock-market-news/astrazeneca-made-10-billion-offer-for-obesity-drugmaker-rhythm-sources-say-5001694) — AstraZeneca made $10 billion offer for obesity drugmaker Rhythm, sources say - [Reuters](https://reuters.com/legal/litigation/astrazeneca-made-10-billion-bid-rhythm-pharmaceuticals-wsj-reports-2026-11-04) — AstraZeneca made $10 billion offer for obesity drugmaker Rhythm, sources say - [dealroom.co](https://dealroom.co/news/169860-reports-astrazeneca-makes-10b-offer-for-rare-obesity-drugmaker-rhythm-ph) — Reports: AstraZeneca makes ~$10B offer for rare-obesity drugmaker Rhythm Pharmaceuticals - [Market Screener](https://marketscreener.com/news/latest/AstraZeneca-made-a-10bn-offer-to-buy-Rhythm-Pharmaceuticals-54664321) — AstraZeneca made a $10bn offer to buy Rhythm Pharmaceuticals - [privataaffarer.se](https://privataaffarer.se/placeringar/aktier/astra-budar-pa-amerikanskt-fetmabolag) — Astra Bids for American Obesity Company - [regionalmedianews.com](https://regionalmedianews.com/news/national/health/astrazeneca-made-10-billion-offer-for-obesity-drugmaker-rhythm-sources-say) — AstraZeneca made $10 billion offer for obesity drugmaker Rhythm, sources say - Regional Media News - [DiarioBitcoin](https://diariobitcoin.com/estados-unidos/astrazeneca-habria-ofrecido-hasta-usd-10-000-millones-por-rhythm) — AstraZeneca Would Have Offered up to $10 Billion for Rhythm - [borskollen.se](https://borskollen.se/nyheter/27/astra-zeneca-vill-kopa-usa-bolag-for-97-miljarder-kronor) — Astra Zeneca Wants to Buy US Company for 97 Billion Kronor - [Dagens industri](https://di.se/live/kallor-astra-lagger-mangmiljardbud) — Sources: Astra Makes Multi-Billion Bid - [WTVB](https://wtvbam.com/2026/11/04/astrazeneca-made-10-billion-bid-for-obesity-drugmaker-rhythm-wsj-reports) — AstraZeneca made $10 billion bid for obesity drugmaker Rhythm, WSJ reports ## Questions **What is AstraZeneca's offer for Rhythm Pharmaceuticals?** AstraZeneca has made a non-binding offer of about $10 billion to acquire Rhythm Pharmaceuticals. This offer values Rhythm at approximately $124 per share, including potential milestone payments. **How did Rhythm Pharmaceuticals' shares react to the news?** Rhythm Pharmaceuticals' shares closed up 28% at $110.68 on November 4, 2026, following the report of AstraZeneca's offer. This increased the company's market capitalization to about $7.64 billion. **Which of AstraZeneca's businesses would handle the acquisition?** The acquisition of Rhythm Pharmaceuticals would be managed through AstraZeneca's rare-disease business unit, Alexion. Alexion specializes in treatments for rare diseases and is part of AstraZeneca's strategy to expand in specialty medicines. --- MediaBias News — https://mediabias.news. Reproduced from https://mediabias.news/business/astrazeneca-offers-10-billion-for-rhythm-pharmaceuticals. Please cite as: MediaBias News, "AstraZeneca offers $10 billion for Rhythm Pharmaceuticals", https://mediabias.news/business/astrazeneca-offers-10-billion-for-rhythm-pharmaceuticals